Boston Scientific : BSX

All Boston Scientific Articles

258 Articles

Douglas A. McIntyre | Sep 14, 2007 at 3:22 AM EDT

Media Digest 9/14/2007 Reuters, WSJ, NYTimes, FT, Barron’s

According to Reuters, Intel (INTC) received antitrust charges from a branch of the South Korean government. Reuters writes that Campbell…

Douglas A. McIntyre | Sep 9, 2007 at 4:29 PM EDT

The Trouble Will Not End For Boston Scientific

Boston Scientific (BSX) has been vexed by problems with its stents, one of its largest businesses. There have been several…

Douglas A. McIntyre | Sep 4, 2007 at 6:59 PM EDT

Boston Scientific (BSX): The Stent Business Can’t Get More Confused

After reports last week that drug-coated stents posed little risk to heart patients, a new survey shows that "patients given…

Douglas A. McIntyre | Sep 3, 2007 at 7:56 AM EDT

Boston Scientific And Johnson & Johnson: Stents Make A Comeback?

http://www.bloomberg.com/apps/news?pid=20601087&sid=ajZ2lVrqeb2I&refer=homeA study out fo Sweden may help the flagging fortunes of the stent businesses at Boston Scientific (BSX) and Johnsohn…

Douglas A. McIntyre | Sep 3, 2007 at 7:18 AM EDT

Media Digest 9/3/2007 Reuters, WSJ, NYTime, FT, Barron’s

According to Reuters, HSBC (HBC) bought 51% of Korea Exchange Bank $6.3 billion. Reuters writes GE (GE) bought buy British…

Douglas A. McIntyre | Aug 17, 2007 at 4:33 AM EDT

The Boston Scientific Fire Sale

Boston Scientific (BSX) has indicated that it will consider selling two more of its units. Wall St. has speculated that…

Douglas A. McIntyre | Aug 17, 2007 at 4:23 AM EDT

Niche Stores Won’t Help Wal-Mart

Wal-Mart (WMT) is thinking of opening a number of high-end stores, focusing on the grocery business. According to The Wall…

Douglas A. McIntyre | Aug 17, 2007 at 3:17 AM EDT

Media Digest 8/17/2007 Reuters, WSJ, NYTimes, FT, Barron’s

According to Reuters, Dell (DELL) will restate four years of results after an audit that lasted over a year. Reuters…

Douglas A. McIntyre | Aug 5, 2007 at 7:11 AM EDT

Will Boston Scientific Be Broken-Up?

The current version of Boston Scientific (BSX) is a merged compeny. The former Guidant sales are the heart rhythm managment…

Douglas A. McIntyre | Aug 3, 2007 at 5:07 AM EDT

Boston Scientific (BSX) Unit IPO Dies On The Table

Boston Scientific (BSX) had planned to take its fast-growing endosurgery group public to raise as much as $1 billion. According…

Douglas A. McIntyre | Aug 3, 2007 at 3:06 AM EDT

Media Digest 8/3/2007 Reuters, WSJ, NYTimes, FT, Barron’s

According to Reuters, net income at Toyota (TM) rose sharply on strong US and European sales. Reuters writes that American…

Douglas A. McIntyre | Jul 27, 2007 at 6:06 AM EDT

Amgen’s (AMGN) Troubled Quarter

Amgen (AMGN) actually rallied a bit after hours yesterday. But, revenue growth was hard to come by. Amgen reported net…

Douglas A. McIntyre | Jul 20, 2007 at 7:41 AM EDT

Stent Blockage Kills Boston Scientific (BSX)

A large drop in the sale of drug coated stents knocked Boston Scientific’s (BSX) quarter way down. The company’s second-quarter…

Douglas A. McIntyre | Jul 14, 2007 at 7:16 AM EDT

Better Medicine For Boston Scientific (BSX)

Boston Scienfitic (BSX) has a deal to "settle all pending federal lawsuits against the company alleging harm from faulty defibrillators…

Douglas A. McIntyre | Jul 13, 2007 at 5:05 PM EDT

Top Earnings Next Week Part 2 (July 19-20, 2007)

THURSDAYAdvanced Micro Devices (NYSDAQ:AMD)Ameritrade (NASDAQ:AMTD)Bank of America (NYSE:BAC)Bank of New York (NYSE:BK)Cemex (NYSE:CX/ADR)Continental Airlines (NYSE:CAL)Cypress Semi (NYSE:CY)Dow Jones (NYSE:DJ)Fifth Third…

1 … 15 16 17 18

Boston Scientific : BSX

All Boston Scientific Articles

Media Digest 9/14/2007 Reuters, WSJ, NYTimes, FT, Barron’s

The Trouble Will Not End For Boston Scientific

Boston Scientific (BSX): The Stent Business Can’t Get More Confused

Boston Scientific And Johnson & Johnson: Stents Make A Comeback?

Media Digest 9/3/2007 Reuters, WSJ, NYTime, FT, Barron’s

The Boston Scientific Fire Sale

Niche Stores Won’t Help Wal-Mart

Media Digest 8/17/2007 Reuters, WSJ, NYTimes, FT, Barron’s

Will Boston Scientific Be Broken-Up?

Boston Scientific (BSX) Unit IPO Dies On The Table

Media Digest 8/3/2007 Reuters, WSJ, NYTimes, FT, Barron’s

Amgen’s (AMGN) Troubled Quarter

Stent Blockage Kills Boston Scientific (BSX)

Better Medicine For Boston Scientific (BSX)

Top Earnings Next Week Part 2 (July 19-20, 2007)

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

Boston Scientific : BSX

All Boston Scientific Articles

Media Digest 9/14/2007 Reuters, WSJ, NYTimes, FT, Barron’s

The Trouble Will Not End For Boston Scientific

Boston Scientific (BSX): The Stent Business Can’t Get More Confused

Boston Scientific And Johnson & Johnson: Stents Make A Comeback?

Media Digest 9/3/2007 Reuters, WSJ, NYTime, FT, Barron’s

The Boston Scientific Fire Sale

Niche Stores Won’t Help Wal-Mart

Media Digest 8/17/2007 Reuters, WSJ, NYTimes, FT, Barron’s

Will Boston Scientific Be Broken-Up?

Boston Scientific (BSX) Unit IPO Dies On The Table

Media Digest 8/3/2007 Reuters, WSJ, NYTimes, FT, Barron’s

Amgen’s (AMGN) Troubled Quarter

Stent Blockage Kills Boston Scientific (BSX)

Better Medicine For Boston Scientific (BSX)

Top Earnings Next Week Part 2 (July 19-20, 2007)

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026